Xilio Therapeutics (XLO) News Today $1.02 -0.02 (-1.92%) (As of 11:54 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Declines By 89.4%November 28, 2024 | americanbankingnews.comPromising Pipeline and Financial Stability Drive Buy Rating for Xilio TherapeuticsNovember 9, 2024 | markets.businessinsider.comXilio Therapeutics Reports Q3 2024 Progress and FinancialsNovember 9, 2024 | markets.businessinsider.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial ResultsNovember 8, 2024 | finance.yahoo.comXilio Therapeutics Advances Cancer Drug and Financial OutlookNovember 8, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Xilio Therapeutics (XLO)November 8, 2024 | markets.businessinsider.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024Â Financial ResultsNovember 7, 2024 | globenewswire.comXilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid TumorsNovember 7, 2024 | globenewswire.comXilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingOctober 30, 2024 | globenewswire.comXilio Therapeutics (NASDAQ:XLO) Stock Quotes, Forecast and News SummaryOctober 17, 2024 | benzinga.comXilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingOctober 4, 2024 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2024 | finance.yahoo.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2024 | globenewswire.comXilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 28, 2024 | globenewswire.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024August 8, 2024 | investorplace.comXilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comXilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.June 13, 2024 | globenewswire.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024May 14, 2024 | investorplace.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsMay 14, 2024 | globenewswire.comXilio Therapeutics (XLO) Price Target Increased by 17.86% to 5.61April 17, 2024 | msn.com3 Biotech Stocks to Invest In Right Now for Long-Term GainsApril 12, 2024 | stocknews.comGilead Sciences, Inc. Buys 485,250 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockApril 4, 2024 | insidertrades.comXLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023April 2, 2024 | investorplace.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsApril 1, 2024 | globenewswire.comXilio Shares Take Flight Premarket After Gilead DealMarch 29, 2024 | marketwatch.comWhy Is Xilio Therapeutics (XLO) Stock up 168% Today?March 28, 2024 | investorplace.comXilio Therapeutics Plans Private Placement, Job CutsMarch 28, 2024 | marketwatch.comXilio Prices Private Placement Of $11.3 Mln Of Shares, Updates XTX202 Trial; To Axe 21% Of JobsMarch 28, 2024 | markets.businessinsider.comTrading was temporarily halted for "XLO" at 09:03 AM with a stated reason of "LULD pause."March 28, 2024 | marketbeat.comTrading was temporarily halted for "XLO" at 09:03 AM with a stated reason of "LULD pause."March 28, 2024 | marketbeat.comXilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingMarch 28, 2024 | globenewswire.comTrading was temporarily halted for "XLO" at 06:03 AM with a stated reason of "News pending."March 28, 2024 | marketbeat.comXilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceFebruary 28, 2024 | globenewswire.comXilio Therapeutics Inc XLOFebruary 27, 2024 | morningstar.comXilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceJanuary 31, 2024 | finance.yahoo.comXilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesJanuary 8, 2024 | finance.yahoo.comWerewolf Therapeutics: Still In The Race To Develop Next Generation CytokinesDecember 28, 2023 | seekingalpha.comXilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataDecember 7, 2023 | finance.yahoo.comXilio Therapeutics GAAP EPS of -$0.61November 10, 2023 | msn.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNovember 9, 2023 | finance.yahoo.comPromising Clinical Trials and Potential Therapies Propel Buy Rating for Xilio TherapeuticsNovember 8, 2023 | markets.businessinsider.comXilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsNovember 3, 2023 | finance.yahoo.comXilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingOctober 31, 2023 | finance.yahoo.comXilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 27, 2023 | finance.yahoo.comXilio Therapeutics Appoints Katarina Luptakova As CMOSeptember 5, 2023 | markets.businessinsider.comXilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 5, 2023 | finance.yahoo.comXilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development OfficerSeptember 5, 2023 | finance.yahoo.comQ2 2023 Xilio Therapeutics Inc Earnings CallAugust 18, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial ResultsAugust 14, 2023 | finance.yahoo.com Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin XLO Media Mentions By Week XLO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XLO News Sentiment▼1.290.87▲Average Medical News Sentiment XLO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XLO Articles This Week▼30▲XLO Articles Average Week Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GOSS News Today DRUG News Today SGMT News Today PBYI News Today PEPG News Today MCRB News Today IVA News Today VTYX News Today TELO News Today SKYE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XLO) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XLO Stock Alerts